Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830206 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00830206: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00830206 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00830206, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The study will compare the relative bioavailability (rate and extent of absorption) of 200 mg/5 mL Azithromycin oral suspension manufactured by TEVA Pharmaceutical Industries Ltd.; distributed by TEVA Pharmaceuticals USA with that of 200 mg/5 mL ZITHROMAX®.
Interventions
- DRUG Zithromax®
- OTHER Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830206
The ClinicalTrials.gov registry entry for NCT00830206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zithromax® is the first listed.
NCT00830206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00830206 about?
NCT00830206 is a clinical study titled "A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions". The study will compare the relative bioavailability (rate and extent of absorption) of 200 mg/5 mL Azithromycin oral suspension manufactured by TEVA Pharmaceutical Industries Ltd.; distributed by TEVA Pharmaceuticals USA with that of 200 mg/5 mL ZITHROMAX®.
What is the current status of trial NCT00830206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2006-01. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00830206?
The interventions under investigation include: Zithromax® (DRUG), Azithromycin (OTHER).
Who is sponsoring clinical trial NCT00830206?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.